Competitive landscape Company filings and websites FDA data EUTECNIQ proposal
Established companies already extract, test and make botanicals; EUTECNIQ proposes the specification and identity work FDA keeps citing
Sixteen companies in six groups that border the services EUTECNIQ proposes, each described from its own filing, annual report, results release or website: reported scale, stated capabilities and the documented quality gaps a new entrant could address.
Status. EUTECNIQ is pre-operational and in formation. It has no laboratory, customers or revenue, and every EUTECNIQ entry here is a management proposal. Company facts were read on October 22, 2026.
Operating models: How EUTECNIQ differs from suppliers, laboratories and manufacturers · Quality and Six Sigma
No named company states more than three of the seven proposed capabilities, and FDA's Part 111 citations reached 1,938 in FY2025Company documents FDA data
16named companies in six groups bordering the proposed services, each from its own documents
3 of 7the most proposed capabilities any one company states in the documents read
1,938Form 483 citations under 21 CFR Part 111 in FY2025, up from 1,218 in FY2022
66identity-test citations, § 111.75(a)(1)(i), in FY2025, up from 15 in FY2023
Who is in the market
Six groups border the proposed services, and the largest companies report health ingredients as one segment among several
Sixteen companies in six groups along the proposed servicesCompany documents
Text version of the six groups
Ingredient majors
Givaudan, dsm-firmenich, IFF, Glanbia
Flavor, nutrition and ingredient groups with health or nutrition segments of €2.1 billion (dsm-firmenich) and $2.3 billion (IFF) in fiscal 2025.
Botanical-extract specialists
Layn, Martin Bauer Group, Indena
Plant extraction is the core business. Layn reports 96.24% of its 2025 revenue from plant-extract products.
Branded-ingredient licensors
Sabinsa, NAI (CarnoSyn), Nuritas
Trademarked or patented ingredients backed by company-funded studies. NAI reported $7.9 million of patent and trademark licensing revenue in fiscal 2026.
Testing laboratories
Eurofins, SGS, Alkemist Labs
From global networks of more than 950 laboratories (Eurofins) to a botanical identity specialist in Garden Grove, California (Alkemist).
Contract manufacturers
NAI, Lonza Capsules & Health Ingredients
Private-label supplement manufacturing in California and Switzerland (NAI); capsules and nutraceutical development (Lonza CHI, being sold to Lone Star Funds).
AI natural-product discovery
Enveda, Brightseed, Nuritas
Machine learning applied to molecules from nature. Enveda reports three development candidates in human trials and more than $845 million raised.
16 companies shown
Show the table (16 rows): Sixteen named companies with base, status, latest reported figure and focus in the company
| Company | Group | Base and status | Latest reported figure | Focus, in the company's words |
|---|---|---|---|---|
| Givaudan | Ingredient majors | Switzerland Publishes annual results releases | Group sales: CHF 7,472M Taste & Wellbeing: CHF 3,642M FY2025 (year to Dec 31, 2025); Full-year results release, January 29, 2026 Group sales up 5.1% like-for-like | Naturex is described by Givaudan as "an international leader in plant extraction and the development of natural ingredients and solutions" for food, health and beauty. |
| dsm-firmenich | Ingredient majors | Kaiseraugst (Switzerland) and Maastricht (Netherlands), dual headquarters Swiss company listed on Euronext Amsterdam | Sales, continuing operations: €9,034M Health, Nutrition & Care: €2,102M FY2025 (year to Dec 31, 2025); Integrated Annual Report 2025, published February 20, 2026 (Note 4, segment information) Animal Nutrition & Health reclassified to discontinued operations at year-end 2025 (sales €3,487M, not included) | Health, Nutrition & Care "provides people a way to look after their health by adding critical nutrients to their diets" (segment description). |
| IFF (International Flavors & Fragrances) | Ingredient majors | New York, NY SEC registrant (Form 10-K) | Net sales: $10,890M Health & Biosciences: $2,283M FY2025 (year to Dec 31, 2025); Form 10-K, filed February 27, 2026 Pharma Solutions divested May 2025 (sales $369M in 2025 included in total) | Within Health & Biosciences, "Health provides ingredients for dietary supplements, functional food and beverage, specialized nutrition and pharma." |
| Glanbia | Ingredient majors | Kilkenny, Ireland (registered office) Public limited company (plc); publishes an annual report | Group revenue: $3,946.4M Health & Nutrition: $628.5M 52 weeks ended Jan 3, 2026; Annual Report 2025 Health & Nutrition revenue +11.5% constant currency | Health & Nutrition "is a global provider of custom premix solutions, value-added ingredients and natural and organic clean label flavour systems." |
| Layn Natural Ingredients (桂林莱茵生物) | Botanical-extract specialists | Guilin, Guangxi, China Listed on the Shenzhen Stock Exchange (002166) | Operating revenue: RMB 2,043.8M Plant-extract products: RMB 1,967.0M FY2025 (year to Dec 31, 2025); 2025 Annual Report (年度报告), March 2026 Revenue +15.36% year on year; plant-extract products 96.24% of revenue | States that it has mastered extraction technology for more than 300 standardized plant components; products include monk fruit, stevia and tea extracts; operates a U.S. extraction plant (BIOVIVO Science, LLC). Our translation. |
| Martin Bauer Group | Botanical-extract specialists | Vestenbergsgreuth, Germany (MB-Holding GmbH & Co. KG) Private; describes itself as a family business | Revenue not disclosed | "Since 1930, MartinBauer has stood for expertise in botanical products": teas, botanical extracts, raw materials and powders for the tea, beverage, food, animal-nutrition and pharmaceutical industries. |
| Indena | Botanical-extract specialists | Main production site in Settala, near Milan, Italy Ownership not stated on the pages reviewed | Revenue not disclosed | Botanical ingredient research, custom development and production "from laboratories, to pilot plants, to full industrial scale" for pharmaceuticals and nutraceuticals; active since 1921. |
| Sabinsa | Branded-ingredient licensors | East Windsor, NJ (U.S. address); parent company Sami Labs Private; revenue not disclosed | Revenue not disclosed | Founded in 1988; producer of "standardized herbal extracts" and branded ingredients such as Curcumin C3 Complex and BioPerine; self-reports "500+ global patents" and "several clinical studies" it funded. |
| Natural Alternatives International (NAI) | Contract manufacturers (CDMOs) | Carlsbad, CA SEC registrant (Form 10-K) | Net sales: $142.5M Private-label contract manufacturing: $134.6M Patent and trademark licensing (CarnoSyn): $7.9M FY2026 (year to Jun 30, 2026); Form 10-K, filed September 28, 2026 Net sales +10% vs FY2025 ($129.860M); net loss in each of fiscal 2024–2026; two largest customers about 52% of net sales | Describes itself as "a leading formulator, manufacturer and marketer of nutritional supplements"; manufacturing in Vista and Carlsbad, California, and Manno, Switzerland; NSF Dietary Supplements certification. Also licenses CarnoSyn beta-alanine. |
| Lonza (Capsules & Health Ingredients) | Contract manufacturers (CDMOs) | Basel, Switzerland Publishes ad hoc announcements under listing rules; CHI being sold to Lone Star Funds | Sales, continuing CDMO business: CHF 6,531M FY2025 (year to Dec 31, 2025); Full-year results release, January 28, 2026; CHI transaction releases March 6 and October 14, 2026 CHI reported as discontinued operations; its 2025 sales are not stated in the results release (CER growth +3.9%) | CHI (Capsugel) describes itself as "a global leader in capsule design, manufacturing and encapsulation technology" and an "end-to-end nutraceutical development partner". Definitive agreement (March 6, 2026) to divest CHI to Lone Star Funds at an enterprise value of CHF 2.3 billion (USD 3 billion), Lonza keeping 40%; closing expected before the end of 2026. |
| Eurofins Scientific | Testing laboratories | Not stated in the release Shares listed on Euronext Paris | Revenues: €7,296M Life (food and feed, agro and environment testing): €3,043M FY2025 (year to Dec 31, 2025); FY2025 results press release, January 29, 2026 Preliminary unaudited results at publication | More than 950 laboratories in 59 countries and "over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity" of products. |
| SGS | Testing laboratories | Baar, Switzerland (company address) Publishes annual results releases (ad hoc announcements) | Sales: CHF 6,945M FY2025 (year to Dec 31, 2025); 2025 full-year results release, February 11, 2026 Organic growth 5.6% | Describes itself as "the world's leading Testing, Inspection and Certification company" with over 2,500 laboratories and business facilities in 115 countries; lists Nutrasource among its brands. |
| Alkemist Labs | Testing laboratories | Garden Grove, CA Ownership not stated; revenue not disclosed | Revenue not disclosed | Founded 1997; botanical "identity verification by HPTLC and microscopy and potency testing by HPLC and GC" under "ISO/IEC 17025 flexible scope accreditation". |
| Enveda | AI natural-product discovery | Boulder, CO Private, venture-financed; revenue not disclosed | Revenue not disclosed | "AI-native platform for identifying biologically active molecules found in nature"; $311 million Series E (September 23, 2026), more than $845 million raised since inception; three development candidates in human trials. |
| Brightseed | AI natural-product discovery | Not stated on the home page Private; revenue not disclosed | Revenue not disclosed | Forager "proprietary discovery foundation and deep science AI" and Hummingbird AI for product-development teams; states "21M+ bioactives" in its data. |
| Nuritas | AI natural-product discovery | Dublin, Ireland Private; revenue not disclosed | Revenue not disclosed | "The Nuritas Magnifier is our proprietary AI platform" to "identify, unlock, and clinically validate smart peptides from nature"; branded peptides include PeptiStrong and PeptiSleep. |
Sources: each company's filing, annual report, results release or website named in the table, read October 22, 2026; full references are on the Sources page. Figures in millions of the reporting currency, not converted. Quotations are the companies' own words; the Layn description is our translation of the Chinese annual report.
Explanation, details and sources
The groups follow the services in EUTECNIQ's plan. A company is listed where its own reporting puts most of its business, and can sit in more than one group.
Method, assumptions and limits
- Selection
- Companies that supply, test, manufacture or discover botanical and supplement ingredients and that publish primary documents (filings, annual reports, results releases) or describe themselves on their own websites. The list is illustrative, not a census; many regional manufacturers and laboratories are not named.
- Figures
- The latest annual figure each company reported as of October 22, 2026, in its reporting currency and in millions, with the label the company uses. No currency conversion, no estimates for private companies, no market shares.
- Capability cells
- Filled only where the company's own document states the capability. Blank cells were not researched further. Self-descriptions such as patent counts are labeled as self-reported.
- Left out
- Statements we could not verify from a company's own pages on the access date, including a sales figure attributed to Kemin Industries in trade press, and companies whose pages we could not read.
- Does not establish
- Product quality, market share, pricing, customer satisfaction or whether any company would work with EUTECNIQ.
- Reproducibility
- Company data: src/modules/compete/compute/raw/competitors.json. FDA counts: fda_part111_trend.py run against FDA's spreadsheets. Both feed build_compete.py, which writes the chart data and the tables on this page.
Reported scale
Reported figures run from a $7.9 million licensing segment to $10.9 billion of net sales, so "competitor" covers very different businesses
Latest reported annual figures, by reporting currency, millions (log scale)Company filings
Show data: reported figures, periods and documents
| Company | Currency | Total, millions | Total as labeled | Segment(s) | Period | Document |
|---|---|---|---|---|---|---|
| Givaudan | CHF | 7,472.000 | Group sales | Taste & Wellbeing: CHF 3,642M | FY2025 (year to Dec 31, 2025) | Full-year results release, January 29, 2026 (results release) |
| dsm-firmenich | EUR | 9,034.000 | Sales, continuing operations | Health, Nutrition & Care: €2,102M | FY2025 (year to Dec 31, 2025) | Integrated Annual Report 2025, published February 20, 2026 (Note 4, segment information) (annual report) |
| IFF (International Flavors & Fragrances) | USD | 10,890.000 | Net sales | Health & Biosciences: $2,283M | FY2025 (year to Dec 31, 2025) | Form 10-K, filed February 27, 2026 (Form 10-K) |
| Glanbia | USD | 3,946.400 | Group revenue | Health & Nutrition: $628.5M | 52 weeks ended Jan 3, 2026 | Annual Report 2025 (annual report) |
| Layn Natural Ingredients (桂林莱茵生物) | CNY | 2,043.840 | Operating revenue | Plant-extract products: RMB 1,967.0M | FY2025 (year to Dec 31, 2025) | 2025 Annual Report (年度报告), March 2026 (annual report) |
| Natural Alternatives International (NAI) | USD | 142.515 | Net sales | Private-label contract manufacturing: $134.6M; Patent and trademark licensing (CarnoSyn): $7.9M | FY2026 (year to Jun 30, 2026) | Form 10-K, filed September 28, 2026 (Form 10-K) |
| Lonza (Capsules & Health Ingredients) | CHF | 6,531.000 | Sales, continuing CDMO business | Not reported separately | FY2025 (year to Dec 31, 2025) | Full-year results release, January 28, 2026; CHI transaction releases March 6 and October 14, 2026 (results release) |
| Eurofins Scientific | EUR | 7,296.000 | Revenues | Life (food and feed, agro and environment testing): €3,043M | FY2025 (year to Dec 31, 2025) | FY2025 results press release, January 29, 2026 (preliminary, unaudited) |
| SGS | CHF | 6,945.000 | Sales | Not reported separately | FY2025 (year to Dec 31, 2025) | 2025 full-year results release, February 11, 2026 (results release) |
Growth and margins of the eight listed companies named here, as each reports them (percent, sortable)Company filings
Show data: growth, margins, definitions and documents
| Company | Fiscal year | Reported revenue growth | Organic or like-for-like growth | EBITDA-type margin | Operating-type margin | Margin definition | Document |
|---|---|---|---|---|---|---|---|
| Givaudan | FY2025 (Dec) | +0.8% | +5.1% like-for-like | 23.4% | n/a | EBITDA margin as reported (comparable 24.2%) | 2025 full-year results media release, Jan 29, 2026 |
| dsm-firmenich | FY2025 (Dec) | −0.2% | +3.0% organic | 19.6% | n/a | adjusted EBITDA margin, continuing operations | Full-year 2025 results press release, Feb 12, 2026 |
| IFF | FY2025 (Dec) | −5.2% | +2.0% comparable currency-neutral | 19.2% | n/a | adjusted operating EBITDA margin | Fourth-quarter and full-year 2025 results (Business Wire), Feb 11, 2026 |
| Glanbia | 52 weeks to Jan 3, 2026 | +2.8% | +2.3% constant currency | 12.6% | n/a | EBITDA pre-exceptional $499.1M ÷ revenue (computed) | Annual Report 2025 |
| Lonza | FY2025 (Dec), continuing CDMO business | +19.2% | +21.7% constant exchange rates | 31.6% | n/a | CORE EBITDA margin | Full-year 2025 results, Jan 28, 2026 |
| Natural Alternatives International | FY2026 (year to Jun 30, 2026) | +9.7% | n/a | n/a | −13.2% | loss from operations $(18.8)M ÷ net sales (computed); includes a $10.4M non-cash impairment | Form 10-K filed Sep 28, 2026; results release Sep 28, 2026 |
| Eurofins Scientific | FY2025 (Dec) | +5.0% | +3.7% organic (4.1% with working-day adjustment) | 22.5% | n/a | adjusted EBITDA margin | FY2025 results press release (preliminary, unaudited), Jan 29, 2026 |
| SGS | FY2025 (Dec) | +2.2% | +5.6% organic | n/a | 16.0% | adjusted operating income margin | 2025 full-year results press release, Feb 11, 2026 |
Margins range from an operating loss at NAI (−13.2%) to a 31.6% CORE EBITDA margin at Lonza's CDMO business.
Explanation, details and sources
Each panel shows one reporting currency, because converting currencies would add an exchange-rate assumption the companies did not make. Filled dots are company totals; open rings are the segment closest to botanical and supplement work, as each company defines it.
Capability coverage
In the documents we read, no company states more than three of the seven capabilities EUTECNIQ proposes to combine
At most three of seven capabilities stated by any one company; EUTECNIQ's row is a proposal for all sevenCompany documents Proposal
Sixteen companies linked to the capabilities their own documents state (grey nodes are capabilities)Company documents
Show data: capabilities stated by each company
| Company | Group | Capabilities stated in the documents read |
|---|---|---|
| Givaudan | Ingredient majors | Plant extraction and standardized botanical ingredients |
| dsm-firmenich | Ingredient majors | Ingredients or premixes for dietary supplements |
| IFF (International Flavors & Fragrances) | Ingredient majors | Ingredients or premixes for dietary supplements |
| Glanbia | Ingredient majors | Ingredients or premixes for dietary supplements |
| Layn Natural Ingredients (桂林莱茵生物) | Botanical-extract specialists | Plant extraction and standardized botanical ingredients |
| Martin Bauer Group | Botanical-extract specialists | Plant extraction and standardized botanical ingredients |
| Indena | Botanical-extract specialists | Plant extraction and standardized botanical ingredients |
| Sabinsa | Branded-ingredient licensors | Plant extraction and standardized botanical ingredients; Branded or licensed ingredients; Clinical studies run, funded or supported |
| Natural Alternatives International (NAI) | Contract manufacturers (CDMOs) | Branded or licensed ingredients; Contract manufacturing of supplements or capsules; Clinical studies run, funded or supported |
| Lonza (Capsules & Health Ingredients) | Contract manufacturers (CDMOs) | Ingredients or premixes for dietary supplements; Contract manufacturing of supplements or capsules |
| Eurofins Scientific | Testing laboratories | Contract analytical testing incl. identity; Clinical studies run, funded or supported |
| SGS | Testing laboratories | Contract analytical testing incl. identity |
| Alkemist Labs | Testing laboratories | Contract analytical testing incl. identity |
| Enveda | AI natural-product discovery | Clinical studies run, funded or supported; AI or computational discovery |
| Brightseed | AI natural-product discovery | AI or computational discovery |
| Nuritas | AI natural-product discovery | Branded or licensed ingredients; Clinical studies run, funded or supported; AI or computational discovery |
Capability matrix with sources
| Company | Plant extraction and standardized botanical ingredients | Ingredients or premixes for dietary supplements | Branded or licensed ingredients | Contract analytical testing incl. identity | Contract manufacturing of supplements or capsules | Clinical studies run, funded or supported | AI or computational discovery | Company source |
|---|---|---|---|---|---|---|---|---|
| Givaudan | Stated | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Naturex acquisition release, September 18, 2018 |
| dsm-firmenich | Not assessed | Stated | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Integrated Annual Report 2025, Note 4 |
| IFF (International Flavors & Fragrances) | Not assessed | Stated | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Form 10-K (segment description) |
| Glanbia | Not assessed | Stated | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Annual Report 2025 (H&N description) |
| Layn Natural Ingredients (桂林莱茵生物) | Stated | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | 2025 Annual Report (business description) |
| Martin Bauer Group | Stated | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Company website |
| Indena | Stated | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Company website |
| Sabinsa | Stated | Not assessed | Stated | Not assessed | Not assessed | Stated | Not assessed | Company website |
| Natural Alternatives International (NAI) | Not assessed | Not assessed | Stated | Not assessed | Stated | Stated | Not assessed | Form 10-K, filed September 28, 2026 ("we also both direct and participate in clinical research studies"; "product testing and evaluation" for private-label customers is not counted as contract testing) |
| Lonza (Capsules & Health Ingredients) | Not assessed | Stated | Not assessed | Not assessed | Stated | Not assessed | Not assessed | Capsugel (Lonza CHI) website |
| Eurofins Scientific | Not assessed | Not assessed | Not assessed | Stated | Not assessed | Stated | Not assessed | FY2025 results press release (About Eurofins) |
| SGS | Not assessed | Not assessed | Not assessed | Stated | Not assessed | Not assessed | Not assessed | About SGS page |
| Alkemist Labs | Not assessed | Not assessed | Not assessed | Stated | Not assessed | Not assessed | Not assessed | Company website |
| Enveda | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Stated | Stated | Press release, September 23, 2026 |
| Brightseed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Stated | Company website |
| Nuritas | Not assessed | Not assessed | Stated | Not assessed | Not assessed | Stated | Stated | Company website |
| EUTECNIQ Proposed | Proposed, not yet built | Proposed, not yet built | Proposed, not yet built | Proposed, not yet built | Proposed, not yet built | Proposed, not yet built | Proposed, not yet built | Management proposal; no capability exists yet |
Explanation, details and sources
- "Not assessed" in this matrix≠The company does not offer the capability
- A capability stated on a website≠Verified quality or capacity
- EUTECNIQ "proposed"≠An existing EUTECNIQ service
"Stated" means the company's own document states the capability; a dash means not assessed. Large groups likely do more than recorded, so this shows coverage of the statements reviewed, not a full audit.
Documented gaps
Specifications topped FDA's supplement citations in each of FY2022–FY2025, and identity-test citations rose from 15 in FY2023 to 66 in FY2025
Form 483 citations under 21 CFR Part 111 by fiscal yearFDA data
Show data
| Fiscal year | Part 111 citations | 111.70 specifications | 111.70 share | 111.75 testing | of which identity test, 111.75(a)(1)(i) | of which supplier qualification, 111.75(a)(2)(ii)(A) | Other Part 111 |
|---|---|---|---|---|---|---|---|
| FY2022 | 1,218 | 271 | 22.2% | 129 | 22 | 25 | 818 |
| FY2023 | 1,173 | 247 | 21.1% | 104 | 15 | 18 | 822 |
| FY2024 | 1,583 | 366 | 23.1% | 173 | 39 | 29 | 1,044 |
| FY2025 | 1,938 | 446 | 23.0% | 265 | 66 | 45 | 1,227 |
What the two sections require
"You must establish an identity specification" for each component.
21 CFR 111.70(b)(1)
Before using a component, "conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient," unless FDA grants an exemption petition.
21 CFR 111.75(a)(1)(i)
eCFR, 21 CFR 111.70 and 111.75, current text retrieved October 22, 2026. Regulation
Adulteration has persisted through fifteen years of documentation
The ABC-AHP-NCNPR Botanical Adulterants Prevention Program began in 2011 and "has published 100 peer-reviewed documents." Its leaders reported in April 2026 that "adulteration of botanical ingredients has persisted." Examples they named include synthetic curcumin in turmeric products, synthetic S-allyl-L-cysteine in garlic extracts, undeclared vitamin C in acerola extracts, citric acid in boswellia extracts and quercetin added to andrographis.
Gafner S, Upton R, Blumenthal M, Khan I. Fifteen years of the ABC-AHP-NCNPR Botanical Adulterants Prevention Program: what have we learned? Oxford International Conference on the Science of Botanicals, April 23, 2026 (abstract). Program report
Academy: why identity testing gates every botanical (Course 2) · identity methods (Course 3)
Explanation, details and sources
FDA publishes counts of the observations its investigators record on Form 483 after inspections. Under 21 CFR Part 111, section 111.70 requires specifications for every component and finished batch, and section 111.75 requires at least one identity test for each dietary ingredient. These two sections drew 711 of 1,938 Part 111 citations in fiscal 2025.
Proposed difference
EUTECNIQ's proposed difference is one accountable path from specification to identity evidence, built to answer the citations above
Each documented gap has a proposed answer a customer could check, and each answer has a stated limitFDA data Proposal
Equivalent services exist in parts today; the proposal is to combine them with development work in one quality system.
Show the table (4 rows)
| Documented gap | Evidence | Proposed EUTECNIQ capability Plan | How a customer could check it | What it would not establish |
|---|---|---|---|---|
| Missing component and finished-batch specifications | 111.70: 446 citations in FY2025, the most-cited Part 111 section each year FY2022–FY2025 | Ingredient specification packages: identity, purity, strength, composition and contaminant limits drafted from pharmacopeial monographs, supplier data and method capability, for the customer's quality unit to approve | A written specification with method references and the justification for each limit | It does not transfer the manufacturer's Part 111 responsibility, which stays with the firm |
| Dietary-ingredient identity not verified | 111.75(a)(1)(i): 66 citations in FY2025, up from 15 in FY2023 | Orthogonal identity testing: chromatographic fingerprint (HPTLC or HPLC) plus macroscopy or microscopy, with DNA methods where suitable, against authenticated reference material | Method validation summaries and reference-material traceability in each report | Identity is not potency, purity or the absence of every adulterant |
| Reliance on supplier certificates without qualification | 111.75(a)(2)(ii)(A): 45 citations in FY2025 | Independent confirmation of supplier certificates of analysis at a frequency the customer sets, with results trended by supplier | Side-by-side records of certificate values and measured values | It is not a supplier audit unless an audit is also performed |
| Economically motivated adulteration | BAPP: 100 peer-reviewed documents since 2011; adulteration "has persisted" | Adulterant-specific screens chosen from BAPP laboratory guidance for each high-risk botanical, for example synthetic curcumin markers in turmeric | The list of screens run on each lot, with detection limits | A negative screen rules out only the adulterants tested for |
Explanation, details and sources
Each capability is a plan tied to a documented gap. A customer could check it through a deliverable, and each has a stated limit.
These services are described in more depth on Quality standards and supplier evaluation, Quality system and Operational excellence.
Partners, customers or rivals
Most of the named companies are more likely to be suppliers, customers or partners than direct rivals
Direct rivalry is expected only with testing laboratories; the other groups are suppliers or partnersPlanning view
Show the table (6 rows)
| Group | Most likely relationship Plan | Reasoning |
|---|---|---|
| Ingredient majors | Suppliers and potential customers | They sell standardized ingredients that EUTECNIQ would test and formulate; their brand customers are the same Part 111 firms EUTECNIQ would serve. EUTECNIQ would not compete on ingredient volume or price. |
| Botanical-extract specialists | Suppliers; occasional rivals in custom extraction | Their scale in sourcing and extraction is not something a new facility would match; development-scale extraction and analytical support could complement it. |
| Branded-ingredient licensors | Licensing and development partners | Branded ingredients need identity methods, stability data and clinical-evidence planning, which are proposed EUTECNIQ services. |
| Testing laboratories | Direct rivals in contract testing; partners for methods EUTECNIQ would not run | Accredited laboratories exist close to EUTECNIQ's proposed Southern California location. They would also be natural partners for interlaboratory comparison and overflow. |
| Contract manufacturers | Manufacturing partners in the early phases | Finished-dosage manufacturing would be placed with qualified partners until EUTECNIQ's own manufacturing phases, which depend on later gates. |
| AI natural-product discovery | Partners | Discovery platforms produce candidates; turning one into a specified, manufacturable and stable ingredient is development and quality work. |
Explanation, details and sources
Direct competition would be strongest with contract testing laboratories. For the other groups, EUTECNIQ's proposed services would sit beside their businesses. This is a planning view, not a description of any existing relationship.
Recent transactions
Disclosed transactions include acquisitions of botanical and capsule businesses and large financings in natural-product discovery
Five disclosed events, 2018 to 2026: one plant-extraction acquisition, two discovery financings and a capsule-business divestmentCompany announcements
These are the companies' own announcements; they describe other companies' businesses and say nothing about EUTECNIQ's value.
Show the table (5 rows)
| Date | Company | Disclosed event | Source |
|---|---|---|---|
| Sep 18, 2018 | Givaudan | Completed the acquisition and delisting of Naturex, which Givaudan described as "an international leader in plant extraction" | Givaudan media release |
| Sep 4, 2025 | Enveda | $150 million Series D | Enveda press page |
| Mar 6, 2026 | Lonza | Definitive agreement to divest Capsules & Health Ingredients to Lone Star Funds at an enterprise value of CHF 2.3 billion (USD 3 billion), retaining a 40% stake | Lonza release (Capsugel site) |
| Sep 23, 2026 | Enveda | $311 million Series E led by Catalio Capital Management; more than $845 million raised since inception | Enveda press release |
| Oct 14, 2026 | Lonza | CHI transaction expected to close before the end of 2026 | Lonza Q3 2026 release |
Market size, estimates and their limits
Retail sales, publisher estimates that disagree by severalfold, and how a bottom-up market estimate should be built.